How Much Revenue Can Roche's Avastin Lose To Pfizer's Biosimilar Zirabev?
The U.S. FDA approved Pfizer's Zirabev on June 27, 2019. Zirabev is a biosimilar to Roche's blockbuster drug, Avastin, which generated revenues of $7 billion in 2018. Avastin could lose more than 20% of its sales over the next few years.
Was Roche's $47 Billion Acquisition of Genentech In 2009 A Bargain?
Roche paid $46.8 billion to acquire Genentech in 2009. Back in 2008, Genentech's top drugs were Avastin, Rituxan, Herceptin, and Lucentis, which generated sales of over $7 billion.
How Does Roche's Herceptin Compare To Other Breast Cancer Drugs?
Herceptin is the leading targeted therapy for the treatment of metastatic HER2 positive breast cancer. HER2 positive breast cancer refers to a type of breast cancer, in which the cells have higher than normal levels of HER2, which is a protein called human epidermal growth factor receptor 2. These cancers tend to grow and spread faster than other breast cancers.
How Much Revenue Does Roche Stand To Lose With Patent Losses of Its Key Oncology Drugs?
Roche's key blockbuster drugs - Herceptin and Avastin - will lose their market exclusivity in 2019, while other blockbuster drug Rituxan has already lost the exclusivity. These 3 drugs are important for Roche as they generate $21 billion in annual sales, representing one-third of the company's total revenues.